Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 6Recruiting 6Completed 4Withdrawn 2Active not recruiting 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 2

Interventions

Oxaliplatin 96Fluorouracil 85Capecitabine 75Gemcitabine 71Leucovorin 69Nivolumab 67Bevacizumab 63pembrolizumab 61Magnetic Resonance Spectroscopy 52Specimen Handling 50Irinotecan 50durvalumab 46Radiotherapy 42atezolizumab 40Cisplatin 40Paclitaxel 38Biopsy 37130-nm albumin-bound paclitaxel 33Cetuximab 29Carboplatin 28Taxes 25Albumin-Bound Paclitaxel 25Drug Therapy 20dehydroftorafur 19Radiation 19Ipilimumab 19tislelizumab 18Docetaxel 18Standard of Care 17trifluridine tipiracil drug combination 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Metronidazole × Gastrointestinal × Clear all
NCT06356597 2026-02-24

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Shanghai Jiao Tong University School of Medicine

Phase 2 Active not recruiting
33 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡